# Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma

> **NCT06191744** · PHASE3 · RECRUITING · sponsor: **Genmab** · enrollment: 1095 (estimated)

## Conditions studied

- Follicular Lymphoma (FL)

## Interventions

- **DRUG:** Epcoritamab
- **DRUG:** Prednisone
- **DRUG:** Rituximab
- **DRUG:** Lenalidomide
- **DRUG:** Doxorubicin
- **DRUG:** Vincristine
- **DRUG:** Cyclophosphamide
- **DRUG:** Obinutuzumab
- **DRUG:** Bendamustine

## Key facts

- **NCT ID:** NCT06191744
- **Lead sponsor:** Genmab
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-02-05
- **Primary completion:** 2037-11
- **Final completion:** 2037-11
- **Target enrollment:** 1095 (ESTIMATED)
- **Last updated:** 2026-05-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06191744

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06191744, "Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT06191744. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*